Search

Abstract Honey bee colony management is critical to mitigating the negative effects of biotic and abiotic stressors. However, there is significant variation in the practices implemented by beekeepers, which results in varying management systems. This longitudinal study incorporated a systems approach to experimentally test the role of three representative beekeeping management systems (conventional, organic, and chemical-free) on the health and productivity of stationary honey-producing colonies over 3 years. We found that the survival rates for colonies in the conventional and organic management systems were equivalent, but around 2.8 times greater than the survival under chemical-free management. Honey production was also similar, with 102% and 119% more honey produced in conventional and organic management systems, respectively, than in the chemical-free management system. We also report significant differences in biomarkers of health including pathogen levels (DWV, IAPV, Vairimorpha apis, Vairimorpha ceranae) and gene expression (def-1, hym, nkd, vg). Our results experimentally demonstrate that beekeeping management practices are key drivers of survival and productivity of managed honey bee colonies. More importantly, we found that the organic management system—which uses organic-approved chemicals for mite control—supports healthy and productive colonies, and can be incorporated as a sustainable approach for stationary honey-producing beekeeping operations.

Endometrial cancer (EC) is the most common gynecological cancer, with rising mortality rates. Targeting non-coding RNAs (ncRNAs) to diagnose and cure endometrial cancer has shown both promise and limitations in recent studies. In comparison to normal tissues, LncRNAs are differentially expressed in ECs, and their dysregulation has been associated to tumor grade, lymph node metastasis, depth of myometrial invasion, FIGO stage and patient survival. Oncogenic lncRNAs (CCAT2, BANCR, NEAT1, MALAT1, LINP1, SRA and LSINCT5) and tumor suppressor lncRNAs (GAS5, MEG3, OIP5-AS1, FER1L4, and LINC00672) have been identified as downstream effectors or upstream modulators of important signaling pathways driving EC metastasis, including the PTEN/PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, WNT/β-catenin, and p53 signaling pathways. Short non-coding RNAs called miRNAs also effect expression of genes at the post-transcriptional level. Multiple studies have shown that miRNAs play a critical role in the regulation of EC. We present a review of ncRNA expression patterns, prognostic significance, biological function and roles in the tumor microenvironment in EC cells in EC associated pathways. We also discuss how ncRNAs can be used as biomarkers for EC diagnosis and as potential therapeutic targets for different EC subtypes based on their ncRNA signature.

Mohit Chauhan,1 Rebecca Parry,1 William V Bobo1,2 1Department of Psychiatry & Psychology, Mayo Clinic Florida, Jacksonville, FL, USA; 2Center for Individualized Medicine, Mayo Clinic Florida, Jacksonville, FL, USACorrespondence: William V Bobo, Department of Psychiatry & Psychology, Mayo Clinic Florida, 4500 San Pablo Blvd, Jacksonville, FL, 32224, USA, Tel +1 904-953-7286, Email bobo.william@mayo.eduAbstract: This article provides an updated review of the pharmacological profile and available efficacy and tolerability/safety data for vilazodone, one of the most recent antidepressant drugs to be approved in the USA for the treatment of major depressive disorder (MDD) in adults. The efficacy of vilazodone for MDD in adults is supported by four positive short-term (8– 10 weeks), randomized, placebo-controlled trials. Beyond these pivotal trials, we review updated research findings pertaining to the clinical effects of vilazodone for MDD including the results of switch studies, small comparative efficacy trials, key pooled and secondary data analyses focused on important depressive subtypes (anxious depression) and predictors of treatment outcome, and safety studies including direct studies of sexual side-effects. Despite these additional research efforts and use for over a decade, important gaps in the clinical evidence base remain with vilazodone. Hypothesized differences in efficacy and adverse effects between other antidepressants and vilazodone based on its multimodal mechanism of action (combining serotonin reuptake inhibition with serotonin 5-HT1A partial agonist effects) have not been comprehensively demonstrated in clinical studies and its effectiveness as a continuation- or maintenance-phase therapeutic is not yet established. Questions remain regarding its reproductive and lactational safety profiles and its efficacy as a potential next-step therapeutic for patients with MDD who do not respond to first-line antidepressants such as selective serotonin reuptake inhibitors. Suggestions for clinical use of vilazodone and discussion of its place among the broad range of pharmacotherapies for adults with MDD are provided.Keywords: vilazodone, major depressive disorder, depression, efficacy, safety, comparative effectiveness